INO Stock News: Inovio Pharmaceuticals Inc extends drop as shares close-in on single digit prices
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NASDAQ:INO falls a further 4.55% on Wednesday amidst broader market selloff.
- Has Inovio fallen too far too fast? Median price target suggests it has.
- Investors continue to jump off as Inovio’s COVID-19 vaccine trials are stuck in neutral.
NASDAQ:INO has extended its slide on Wednesday as investors remain anxious about the FDA investigation into its vaccine candidate INO-4800 and the delivery device, CELLECTRA 2000. Inovio fell once again on Wednesday, shedding 4.55% to close the trading session at $10.50. As other biotech firms continue to inch closer to a successful vaccine candidate for the novel coronavirus, Inovio remains mired in an FDA inquiry with questions about its clinical trials.
Investors have every right to take their money and invest it elsewhere as there are plenty of horses in the COVID-19 vaccine race that are worth backing. While Inovio is stuck in the mud with its clinical trials on hold, other companies like Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and Pfizer (NYSE:PFE) are all nearing or currently in Phase 3 of their respective studies. While realistically, it was probably a longshot for a company as small as Inovio to bounce these pharmaceutical titans from Operation Warp Speed, but investing in micro-cap biotech stocks is always an enticing endeavor for investors looking for large gains in a short amount of time.
Inovio Pharmaceuticals stock chart
When will the bleeding stop for Inovio? It is difficult to say. Surely, when the FDA gives the go-ahead to resume clinical trials for INO-4800, the stock will see a surge back up from bargain investors looking to buy the dip. It remains to be seen if that is truly warranted for Inovio though, as other companies with stable track records ready their vaccine candidates for large scale distribution, Inovio looks like it will find itself on the outside looking in.
- NASDAQ:INO falls a further 4.55% on Wednesday amidst broader market selloff.
- Has Inovio fallen too far too fast? Median price target suggests it has.
- Investors continue to jump off as Inovio’s COVID-19 vaccine trials are stuck in neutral.
NASDAQ:INO has extended its slide on Wednesday as investors remain anxious about the FDA investigation into its vaccine candidate INO-4800 and the delivery device, CELLECTRA 2000. Inovio fell once again on Wednesday, shedding 4.55% to close the trading session at $10.50. As other biotech firms continue to inch closer to a successful vaccine candidate for the novel coronavirus, Inovio remains mired in an FDA inquiry with questions about its clinical trials.
Investors have every right to take their money and invest it elsewhere as there are plenty of horses in the COVID-19 vaccine race that are worth backing. While Inovio is stuck in the mud with its clinical trials on hold, other companies like Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and Pfizer (NYSE:PFE) are all nearing or currently in Phase 3 of their respective studies. While realistically, it was probably a longshot for a company as small as Inovio to bounce these pharmaceutical titans from Operation Warp Speed, but investing in micro-cap biotech stocks is always an enticing endeavor for investors looking for large gains in a short amount of time.
Inovio Pharmaceuticals stock chart
When will the bleeding stop for Inovio? It is difficult to say. Surely, when the FDA gives the go-ahead to resume clinical trials for INO-4800, the stock will see a surge back up from bargain investors looking to buy the dip. It remains to be seen if that is truly warranted for Inovio though, as other companies with stable track records ready their vaccine candidates for large scale distribution, Inovio looks like it will find itself on the outside looking in.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.